Pharmascience Korea will seek approval via the Korea Food and Drug Administration to market Pharmascience’s generic medicines in Korea by mid-2014.

Pharmascience, which was founded in 1983, manufactures generic drugs in a number of key therapeutic areas, including cardiovascular health, gastroenterology, central nervous system, anti-inflammatory and anti-infectives, among others. Their medicines portfolio includes more than 1,000 formats in wide range of dosage forms–everything from powders and tablets to capsules to suppositories.

The initial product portfolio for Pharmascience Korea will focus on generics of central nervous system medications to treat a variety of psychiatric disorders. The generics will be manufactured by Pharmascience at its state-of-the-art facility in Montreal, Canada, which underwent a US$40 million expansion and upgrade in 2011.

The companies will contribute 50:50 to the partnership, which is expected to enable Pharmascience to establish a significant presence in the important Korean pharmaceutical market by making use of Kolmar’s local expertise.

The Korean generic drug market is ranked the 13th largest in the world, while that of Canada is ranked 10th.

Related articles

Teva makes South Korean joint venture agreement

Biosimilars boost for South Korea

Permission granted to reproduce for personal and educational use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.